HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00473434

Paliperidone doses after switching from another antipsychotic

About this titleRead the official source — NCT00473434
Medication studyAges 18–65Schizophrenia
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateApril 2007
Recruitment status
Completed
Enrollment listed in the registry
64
Sponsor
Janssen-Cilag Pty Ltd
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Not clearly listed
Age range
From 18 Years to 65 Years
Official registry ID
NCT00473434
Official title
Show the full official title

An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Janssen-Cilag Pty Ltd.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies